Jennifer Davagian-Ensign is the Founder and CEO of Christcot Medical Company. As a Crohn’s patient she knows the daily struggles of IBD patients and compliance decisions affecting healthcare outcomes. Ms. Davagian-Ensign has given several talks including patient responsibility in compliance and the importance of new medical device technologies that motivate behavioral changes on the part of the patient. As a thought leader in the area of rectal medication treatment for gastrointestinal disease, Ms. Davagian-Ensign led the initiative to have Ulcerative Proctitis categorized as a Rare Genetic Orphan Disease by the NIH and wrote the abstract included in the NIH database. Jennifer Davagian-Ensign is the Founder and CEO of Christcot Medical Company. As a Crohn’s patient she knows the daily struggles of IBD patients and compliance decisions affecting healthcare outcomes. Ms. Davagian-Ensign has given several talks including patient responsibility in compliance and the importance of new medical device technologies that motivate behavioral changes on the part of the patient. As a thought leader in the area of rectal medication treatment for gastrointestinal disease, Ms. Davagian-Ensign led the initiative to have Ulcerative Proctitis categorized as a Rare Genetic Orphan Disease by the NIH and wrote the abstract included in the NIH database.

Gastroenterology